Evidence & concentration worksheet · Metabolic & Weight Loss
Cagrilintide 10 mg
Controlled trials exist, but there is no approved consumer product or prescribing label. Trial doses apply only inside their monitored study designs, not to online research vials.
Evidence review
Investigational trial context — not self-use instructions
Controlled trials exist, but there is no approved consumer product or prescribing label. Trial doses apply only inside their monitored study designs, not to online research vials.
How it works
Cagrilintide is a long-acting amylin analogue being developed for chronic weight management, both alone and with semaglutide as CagriSema. It has a genuine late-stage clinical program, but an investigational ingredient is not interchangeable with an online “research” vial.
Benefits & side effects
In a 706-participant phase 2 trial, cagrilintide alone produced greater mean weight reduction than placebo at 26 weeks; gastrointestinal events and injection-site reactions were common.[1] In the 3,417-participant REDEFINE 1 phase 3 trial, cagrilintide 2.4 mg plus semaglutide 2.4 mg produced an estimated 20.4% mean weight reduction at 68 weeks versus 3.0% with placebo.[2] A separate phase 3 trial reported benefit in adults with overweight or obesity and type 2 diabetes.[3]
Combination results cannot be attributed entirely to cagrilintide, and trial products, titration, eligibility criteria, monitoring, and follow-up do not validate independently sold material.
Calculator
Concentration and measurement calculator
Use this only to check arithmetic from an authoritative product label, registered study protocol, or qualified clinician.
Arithmetic only — not a dose recommendation
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Source concentration
Source-supplied target
References
References
- The Lancet — Once-weekly cagrilintide for weight management: phase 2 trial (2021)
- New England Journal of Medicine — Coadministered cagrilintide and semaglutide in adults with overweight or obesity (2025)
- New England Journal of Medicine — Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes (2025)
- U.S. FDA — Prime Sciences warning letter (2026)
- U.S. FDA — Cagrilintide substance registration record (2026)
Other vial sizes